Additionally, one study of diagnosis-to-relapse FLT3-ITD patients demonstrated that XPO1 expression increased at time of relapse and inhibition of XPO1 with selinexor increased sensitivity to induction chemotherapy used for AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.